Qianjiang Yongan Pharmaceutical Co., Ltd.

Sümbol: 002365.SZ

SHZ

8.24

CNY

Turuhind täna

1753.8874
P/E suhe
28.8139
PEG suhe
2.43B
MRK Cap
0.01%
DIV tootlus

Qianjiang Yongan Pharmaceutical Co., Ltd. (002365-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 733.083 M, mis on 0.143 % gowth. Kogu perioodi keskmine brutokasum on 199.898 M, mis on 0.146 %. Keskmine brutokasumi suhtarv on 0.275 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -1.088 %, mis on võrdne 0.163 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Qianjiang Yongan Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.032. Käibevara valdkonnas on 002365.SZ aruandlusvaluutas 1213.596. Märkimisväärne osa neist varadest, täpsemalt 956.545, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 0.149%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 68.3, kui neid on, aruandlusvaluutas. See näitab erinevust -114.345% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 0 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.182%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 1983.913 aruandlusvaluutas. Selle aspekti aastane muutus on -0.017%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 178.359, varude hind on 69.9 ja firmaväärtus 0.52, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 82.39.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006
balance-sheet.row.cash-and-short-term-investments	3696.04	956.5	832.2	547.5	748.3	502	57.7	149.7	105.3	59.4	30.6	124.1	220.8	227.3	517.6	76.7	121.3	37.9	16.7
balance-sheet.row.short-term-investments	2581.9	630.4	557.5	454	634.1	384.7	34.7	17.3	16.3	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	794.98	178.4	203.1	367.8	196.9	148.8	162.9	176.9	103.4	105	111	135	146.3	191	138.9	81.7	56.7	78.5	45.1
balance-sheet.row.inventory	310.95	69.9	149.6	145.8	81.7	104.1	97.4	80.5	61.2	52.9	43.7	26	19.9	18	19.4	9.3	9.5	14.1	8.8
balance-sheet.row.other-current-assets	21.25	8.8	10.4	4.8	0.7	2	449	315.7	360.8	298.1	281.8	210	180	250	150	-1.3	-1.3	-1.7	-6.7
balance-sheet.row.total-current-assets	4823.23	1213.6	1195.3	1065.9	1027.5	757	766.9	722.7	630.7	515.3	467.2	495.1	567	686.3	825.9	166.5	186.2	128.7	63.9
balance-sheet.row.property-plant-equipment-net	3948.37	970.9	1023.5	989.3	990.5	1010.2	1017.4	665.3	556.2	596.2	634.1	621.2	566.8	397.5	209.4	170.7	145	77.1	69.4
balance-sheet.row.goodwill	18.57	0.5	8.8	8.8	8.8	8.8	8.8	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	331.84	82.4	84.5	87.9	89.8	88.2	88.6	92.6	78.9	82.7	79.1	81.8	72.3	71.8	50.4	51.5	42.5	43.4	17.4
balance-sheet.row.goodwill-and-intangible-assets	350.41	82.9	93.3	96.7	98.6	97	97.4	92.6	78.9	82.7	79.1	81.8	72.3	71.8	50.4	51.5	42.5	43.4	17.4
balance-sheet.row.long-term-investments	-926.92	68.3	-476.1	-338.8	-598.8	-352.7	1.8	1.9	1.9	2	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	40.83	11.3	9.7	9.9	9.4	7.1	5.4	6	4.1	4.5	4.5	4.3	4.7	4.9	5	5.3	5.4	5.3	0.2
balance-sheet.row.other-non-current-assets	1311.93	0.1	578.5	462.9	636.6	389.2	40.1	91.5	1.5	2.2	2	0	0	0	0	0	0	0	0.3
balance-sheet.row.total-non-current-assets	4724.61	1133.5	1228.8	1220	1136.2	1150.8	1162.1	857.2	642.6	687.6	719.8	707.3	643.8	474.1	264.8	227.5	192.9	125.7	87.3
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	9547.85	2347.1	2424.2	2285.9	2163.7	1907.8	1929	1579.9	1273.3	1203	1187	1202.4	1210.8	1160.4	1090.7	394	379.2	254.4	151.2
balance-sheet.row.account-payables	542.02	128.8	162.8	114.9	97.6	111.2	142.4	47.9	38.6	43.6	32.2	69.2	58.1	47.1	15.3	20.7	17.1	15.4	24.5
balance-sheet.row.short-term-debt	93.03	47.3	40	20.4	122.3	3	2	0	10.1	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-payables	56.99	7.8	4.9	5.5	5.2	8.8	15.5	5.3	2.3	1.7	6.5	2.8	16	13	15.3	0	28.6	12	1.9
balance-sheet.row.long-term-debt-total	0	0	0	0	0	0	0	0	-18.8	0	0	0	0	0	0	0	0	0	0
Deferred Revenue Non Current	35.42	8.5	11.3	13.1	14.2	14.7	16.5	20.6	18.8	24	29.2	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	114.65	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	161.86	65.6	70.6	78.5	24.2	22.2	114.9	165.9	5.5	15.4	17.3	19.9	21.6	19.1	20.1	9.8	68.6	15.3	19.3
balance-sheet.row.total-non-current-liabilities	141.57	33.1	36	35.6	39.7	43.2	48.4	21.4	19.1	24.5	29.6	33.4	36.8	38	40.7	39.3	34.4	32.2	2.5
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	1163.17	290.3	321.2	328.9	349.9	251.1	323.1	235.2	96.2	83.5	79.1	122.5	116.6	104.1	76.1	69.8	120	62.9	46.2
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	1178.73	294.7	294.7	294.7	294.7	294.7	294.7	196.5	187	187	187	187	187	187	93.5	70	70	70	50
balance-sheet.row.retained-earnings	3406.61	812.7	854.5	728.2	656.5	603.8	549.4	410.4	312	262.7	259.4	238.1	255.9	225.7	191	196.2	137.7	80.4	33.7
balance-sheet.row.accumulated-other-comprehensive-income-loss	2079.42	163.8	155.4	130.9	119.8	16.8	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	1425.56	712.8	712.8	712.2	684.7	697.6	735.9	734.3	674.3	665.7	661.5	654.7	651.3	643.6	730.1	57.9	51.4	41.2	21.3
balance-sheet.row.total-stockholders-equity	8090.32	1983.9	2017.4	1865.9	1755.7	1612.9	1579.9	1341.1	1173.3	1115.4	1107.9	1079.9	1094.2	1056.3	1014.6	324.2	259.1	191.5	105
balance-sheet.row.total-liabilities-and-stockholders-equity	9547.85	2347.1	2424.2	2285.9	2163.7	1907.8	1929	1579.9	1273.3	1203	1187	1202.4	1210.8	1160.4	1090.7	394	379.2	254.4	151.2
balance-sheet.row.minority-interest	285.85	64.4	85.6	91.1	58.1	43.8	26	3.6	3.8	4.1	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	8376.17	2048.3	2103	1957	1813.8	1656.7	1605.9	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	9547.85	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	1654.98	698.7	81.4	115.2	35.3	32	34.7	17.3	16.3	2	0	0	0	0	0	0	0	0	0.3
balance-sheet.row.total-debt	93.03	47.3	40	20.4	122.3	3	2	0	10.1	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-debt	-1021.1	-278.9	-234.7	-73.1	8.2	-114.3	-21	-132.4	-79	-59.4	-30.6	-124.1	-220.8	-227.3	-517.6	-76.7	-121.3	-37.9	-16.7

Rahavoogude aruanne

Qianjiang Yongan Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.481 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -166049062.000. See on -0.279 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 135.18, 45.21, -30, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -29.47 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui -6.3, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006
cash-flows.row.net-income	1.38	-12.3	132.7	119	118.7	106.9	178.9	133	62	17.2	31.7	23	75.4	69.8	46.1	65.1	102.6	68.9	37.5
cash-flows.row.depreciation-and-amortization	0.09	135.2	123.6	116	113.1	112.8	79.8	69.9	71.4	69.8	55.7	40.4	18.9	16.4	13.4	10.7	7.8	6.5	0
cash-flows.row.deferred-income-tax	0	6.8	2.4	-3.8	-5.4	-5	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	0	-176.9	0.9	12.4	1.5	5	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	106.58	93.5	99.1	-152.4	-26.4	15.4	68.4	-21.1	-35.6	-11.5	-66.3	7.7	-14.9	10.1	-14	-40.5	49.2	-15.7	0
cash-flows.row.account-receivables	18.85	18.9	163.2	-172.1	-66.9	9.6	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	87.73	87.7	-10	-63.7	19.3	-7.5	-16.9	-19.3	-8.3	-9.1	-17.8	-6.1	-1.8	1.3	-10	0.1	4.6	5.2	0
cash-flows.row.account-payables	0	-13.1	-56.5	87.2	26.5	18.3	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	0	0	2.4	-3.8	-5.4	-5	85.3	-1.9	-27.3	-2.4	-48.5	13.8	-13.1	8.8	-3.9	-40.6	44.6	-20.9	0
cash-flows.row.other-non-cash-items	71.81	197.9	28.5	10.7	5.2	4.5	-13.1	15.6	-13.2	-4.8	-1.8	-7.4	-8.6	-5.1	-1.5	1.2	-1.1	1.3	-37.5
cash-flows.row.net-cash-provided-by-operating-activities	179.87	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-119.09	-120.7	-149.1	-63	-104.4	-134.4	-269.5	-289.5	-40.1	-34.1	-50.7	-99.9	-120.2	-248	-104.5	-46	-72.2	-60.8	-17.7
cash-flows.row.acquisitions-net	0.87	1	0.4	-35.9	105.1	135.4	0	0	40.1	34.4	-0.7	100.3	0	248	0	0	0	0	0
cash-flows.row.purchases-of-investments	-1350.13	-1484.2	-1110.7	-823.2	-1215.7	-607	-698.8	-56.8	-52.2	-14	-69	-30	0	-100	-150	0	0	0	0
cash-flows.row.sales-maturities-of-investments	1299.19	1392.7	1029	943.5	988.4	692.9	551.5	91.5	30.6	12.6	10.4	8.7	78.5	6.6	1.5	0	0	0.4	0.1
cash-flows.row.other-investing-activites	22.57	45.2	0	0.5	-104.4	-134.4	8.2	6.1	-40.1	-34.1	2.8	-99.9	1.8	-248	-9.5	0	0	11.3	0.1
cash-flows.row.net-cash-used-for-investing-activites	-123.95	-166	-230.4	21.8	-331.1	-47.4	-408.5	-248.5	-61.7	-35.3	-107.2	-120.9	-39.8	-341.4	-262.6	-46	-72.2	-49.1	-17.5
cash-flows.row.debt-repayment	-10.6	-30	-40	-132.3	-21	-7	0	-9.8	0	0	0	0	0	0	0	0	0	-30	-6
cash-flows.row.common-stock-issued	0	0	0	0	57.7	70.9	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	-4.9	-70.9	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-44.62	-29.5	-1.6	-30.7	-45.5	-30.1	-19.7	-18.8	-5.6	-11.2	-5.6	-39.4	-37.4	-30.5	-42.3	-35	-2.9	-12.7	-0.2
cash-flows.row.other-financing-activites	-2.27	-6.3	59.4	23.8	136.2	-62.1	3.7	139.8	-1.9	4.5	0	0	0	0	692.2	0	0	52	0
cash-flows.row.net-cash-used-provided-by-financing-activities	-41.19	-65.8	17.8	-139.2	122.4	-99.1	-16	111.2	-7.6	-6.7	-5.6	-39.4	-37.4	-30.5	649.9	-35	-2.9	9.2	-6.2
cash-flows.row.effect-of-forex-changes-on-cash	10.45	7.1	6.5	-1.1	-5.2	1.4	1.1	-4.6	2.3	0.2	0	-0.1	0	-0.1	0	0	0	0	0
cash-flows.row.net-change-in-cash	9.69	51.5	181.2	-16.7	-7.1	94.4	-109.4	55.3	17.6	28.8	-93.5	-96.7	-6.4	-280.8	431.3	-44.5	83.4	21.2	7.5
cash-flows.row.cash-at-end-of-period	1070.94	326.2	274.7	93.5	110.2	117.3	23	132.4	77	59.4	30.6	124.1	220.8	227.3	508.1	76.7	121.3	37.9	16.7
cash-flows.row.cash-at-beginning-of-period	1061.25	274.7	93.5	110.2	117.3	23	132.4	77	59.4	30.6	124.1	220.8	227.3	508.1	76.7	121.3	37.9	16.7	9.2
cash-flows.row.operating-cash-flow	179.87	244.3	387.3	101.8	206.7	239.5	314	197.3	84.5	70.6	19.3	63.6	70.7	91.2	44.1	36.4	158.5	61.1	0
cash-flows.row.capital-expenditure	-119.09	-120.7	-149.1	-63	-104.4	-134.4	-269.5	-289.5	-40.1	-34.1	-50.7	-99.9	-120.2	-248	-104.5	-46	-72.2	-60.8	-17.7
cash-flows.row.free-cash-flow	60.78	123.5	238.2	38.8	102.3	105.2	44.5	-92.2	44.4	36.5	-31.4	-36.3	-49.4	-156.8	-60.5	-9.5	86.3	0.3	-17.7

Kasumiaruande rida

Qianjiang Yongan Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga -0.342%. 002365.SZ brutokasum on teatatud 229.28. Ettevõtte tegevuskulud on 205, mille muutus võrreldes eelmise aastaga on -36.004%. Kulud amortisatsioonikulud on 135.18, mis on -0.191% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 205, mis näitab -36.004% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.841% kasvu võrreldes eelmise aastaga. Tegevustulu on 24.28, mis näitab -0.841% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -1.088%. Eelmise aasta puhaskasum oli -12.31.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006
income-statement-row.row.total-revenue	852.45	962.8	1462.4	1565.4	1172.9	1370.4	1005.4	932.8	549.4	555.9	658.4	522.7	470.7	417	319.7	310.3	447.5	315	156.7
income-statement-row.row.cost-of-revenue	643.48	733.5	980.8	1206.9	816.5	1051.7	655.4	592.5	408.4	457.3	556.8	437.8	342.6	314.4	239.4	207.6	284.4	210	101.3
income-statement-row.row.gross-profit	208.97	229.3	481.7	358.5	356.3	318.7	350	340.3	141	98.6	101.6	84.9	128.1	102.6	80.3	102.7	163.1	105	55.4
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	41.02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	73.14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	18.03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-94.9	-1.2	66.2	69.7	43.4	44	0	5	11.1	7.6	5.9	5.3	-1.2	3	4.8	2.4	1.1	1.1	-0.1
income-statement-row.row.operating-expenses	280.6	205	320.3	228.6	218.4	202.2	161.6	160.2	99.7	97.3	73.3	67.9	51.3	34.1	40.8	29.1	39.1	29.7	15.2
income-statement-row.row.cost-and-expenses	924.08	938.5	1301.1	1435.4	1034.9	1253.9	816.9	752.6	508.1	554.6	630.1	505.6	393.9	348.5	280.1	236.6	323.5	239.7	116.6
income-statement-row.row.interest-income	1.56	1.9	0.3	0.2	1.5	2.6	2.9	1.3	0.9	1	1	3.8	0	7.7	8.7	1.7	1	0	0
income-statement-row.row.interest-expense	0.4	0.4	0.7	2.4	1.2	0.3	0	0.1	8.1	7.4	1.1	0	-6.1	0	0	0	0	3.5	1
income-statement-row.row.selling-and-marketing-expenses	18.03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	66.41	-20.9	0.7	-1.8	-3.4	-1.3	23.6	-23.3	32.1	19.6	8.9	10.6	11.9	12.5	12	1.4	-3.2	-3.4	-1.7
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-94.9	-1.2	66.2	69.7	43.4	44	0	5	11.1	7.6	5.9	5.3	-1.2	3	4.8	2.4	1.1	1.1	-0.1
income-statement-row.row.total-operating-expenses	66.41	-20.9	0.7	-1.8	-3.4	-1.3	23.6	-23.3	32.1	19.6	8.9	10.6	11.9	12.5	12	1.4	-3.2	-3.4	-1.7
income-statement-row.row.interest-expense	0.4	0.4	0.7	2.4	1.2	0.3	0	0.1	8.1	7.4	1.1	0	-6.1	0	0	0	0	3.5	1
income-statement-row.row.depreciation-and-amortization	59.89	135.2	167.1	132.3	130.7	130.2	79.8	69.9	71.4	69.8	55.7	40.4	18.9	16.4	13.4	10.7	7.8	6.5	2.2
income-statement-row.row.ebitda-caps	-1.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-43.84	24.3	152.4	131.7	134	117.6	212.3	151.8	62.9	13.4	32.7	22.4	89.8	78	46.8	72.6	119.7	71.1	38.5
income-statement-row.row.income-before-tax	22.57	3.4	153.1	129.9	130.6	116.4	212.1	156.9	73.3	20.9	37.2	27.7	88.7	81	51.6	75	120.8	71.9	38.4
income-statement-row.row.income-tax-expense	38.46	34.5	20.3	10.8	11.9	9.4	33.2	23.9	11.3	3.7	5.5	4.7	13.3	11.2	5.5	10	18.2	2.9	1
income-statement-row.row.net-income	1.38	-12.3	140.3	111.4	105.6	89.9	178.6	133.2	62.3	17.6	31.7	23	75.4	69.8	46.1	65.1	102.6	68.9	37.5